Mometason Abece (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside nasal epithelial cells. This binding modifies gene expression, suppressing the production of inflammatory cytokines and chemokines while promoting anti‑inflammatory proteins. The overall effect is reduced swelling, less mucus production, and decreased infiltration of inflammatory cells, which alleviates nasal symptoms.

The appropriate dose of Mometason Abece is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and the product label; the regimen is not standardized and must be individualized.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Healthcare providers generally weigh the potential benefits against possible risks before prescribing it to pregnant or nursing women. Patients should discuss their specific situation with a physician before starting treatment.

To request Mometason Abece, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mometason Abece contains mometasone furoate, a high‑potency corticosteroid with strong local anti‑inflammatory activity and minimal systemic absorption. Compared with older agents such as beclomethasone or fluticasone, mometasone often provides effective symptom control at lower daily doses, though individual response and tolerability can vary.

Mometason Abece should be stored at room temperature, ideally below 25 °C (77 °F). Keep the spray in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use to maintain product stability.

The spray is used intranasally. The patient gently shakes the bottle, inserts the nozzle into one nostril while keeping the head upright, and sprays the prescribed number of sprays as directed by the prescriber. The same procedure is repeated in the other nostril if required.

Serious adverse events, though rare, include nasal septal perforation, severe or persistent nosebleeds, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal cavity. Patients should seek immediate medical attention if they experience unusual bleeding, vision changes, or signs of infection.

Mometason Abece is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided in patients with active untreated nasal infections, recent nasal surgery without physician approval, or those who have experienced severe adverse reactions to other nasal corticosteroids.